Liver Cancer Drugs Market Size, Share, Growth Analysis, By Drug (Targeted Therapy, Immunotherapy), By Type (Hepatocellular Carcinoma, Cholangio Carcinoma), By Distribution Chanel (Hospital Pharmacy, Online Pharmacy), By Region - Industry Forecast 2025-2032


Report ID: SQMIG35B2174 | Region: Global | Published Date: December, 2024
Pages: 157 |Tables: 114 |Figures: 67

Liver Cancer Drugs Market Insights

Liver Cancer Drugs Market size was valued at USD 3.18 Billion in 2023 and is poised to grow from USD 3.74 Billion in 2024 to USD 13.64 Billion by 2032, growing at a CAGR of 17.6% during the forecast period (2025-2032).

The availability of novel drugs, the presence of strong pipelines, and rising public awareness are among the key trends escalating market growth. Besides this, growing incidence of liver cancer due to increasing geriatric population and unorganized lifestyle is estimated to provide a fillip to the market. Hepatocellular carcinomas (HCCs) account for the majority (75–90%) of primary liver cancers. A significant number of etiological factors of liver cancer, including hepatitis infection and cirrhosis, are modifiable and present a strong prospect to reduce its incidence and mortality by preventive strategies such as lifestyle modification and hepatitis immunization.

North America and Southern Europe have the highest incidence of mortality ratios for liver cancer. Incidence rates varied geographically, with the highest incidence rates for males recorded in Eastern Asia (31.9 per 100,000) and South-Eastern Asia (22.2 per 100,000). The highest incidence rates for females were reported in Eastern Asia (10.2 per 100,000) and Western Africa (8.1 per 100,000)

US Liver Cancer Drugs Market is poised to grow at a sustainable CAGR for the next forecast year.

To get more reports on the above market click here to Buy The Report

Liver Cancer Drugs Market Segmental Analysis

Global Liver Cancer Drugs Market is segmented by Drug, Type, Distribution Chanel, and region. Based on Drug, the market is segmented into Targeted Therapy, Immunotherapy, and Chemotherapy. Based on Type, the market is segmented into Hepatocellular Carcinoma, Cholangio Carcinoma, Hepatoblastoma, and Others. Based on Distribution Chanel, the market is segmented into Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.  

Liver Cancer Drugs Market Analysis By Distribution Channel

Based on the distribution channel, In 2022, the segment made up of hospitals and diagnostic labs held the majority of the market. The majority of people receive their primary diagnosis and care in hospitals. Conditions such as cholangiocarcinoma, Hepatocellular Carcinoma (HCC), and others require facilities for disease management & treatment in a long-term manner.Moreover, hospitals & diagnostic laboratories provide patients with cost-effective screening products. This segment is expected to grow during the forecast period due to the availability of skilled professionals, cutting-edge techniques, sample collection, and highly sensitive data in one location.

The hospital segment will maintain its dominance thanks to rising patient numbers and prescription drug sales for treating liver cancer disorders, particularly hepatocellular carcinoma. Additionally, the growing trend among customers to frequently purchase goods from nearby pharmacies is assisting in the expansion of this market. Due to the penetration of online pharmacies in both developing and developed countries, the segment of online pharmacies is anticipated to experience a profitable CAGR during the forecast period.

To get detailed analysis on other segments, Request For Free Sample Report

Liver Cancer Drugs Market Regional Insights

North America held the dominant share with an estimated 40.37% share earned in 2022. This is owing to the presence of well-established healthcare infrastructure, coupled with an extensive reimbursement framework. Additionally, the increasing implementation of novel diagnostics, and adoption of healthcare insurance policies will further help this region continue dominance. Furthermore, due to the rising incidence of various tumor cases, supportive government organizations such as IARC, CDC, and NIH, the research & development of new testing & screening methods is also projected to help promote market growth.

Asia Pacific on the other hand, is projected to witness the highest growth rate during the forecast years. This is attributed to the significant growth of the geriatric population exposed to risk factors in developing nations. Additionally, rise in initiatives by governments & private organizations to improve access to healthcare are also promoting market growth.

To know more about the market opportunities by region and country, click here to
Buy The Complete Report

Liver Cancer Drugs Market Dynamics

Liver Cancer Drugs Market Drivers

Rise in Number of Smokers, and Alcoholics Leads to Liver Issues

  • One million new cases of liver cancer are diagnosed worldwide each year. The increase in prevalence of people consuming alcohol and following smoking habits is projected to aid in market expansion during the forecast period. Liver cancer is mainly caused by smoking, alcohol, and increased urbanization. The global market for liver cancer drugs is being positively impacted by increased government help and investments from international healthcare institutions. The availability of many liver cancer drugs may soon increase demand.
  • The debut of new drugs and rising FDA approvals for treating hepatocellular carcinoma, which accounts for nearly 90% of all liver cancer markets, are the results of the more aggressive R&D efforts against harmful diseases.

Liver Cancer Drugs Market Restraints

Strict Regulatory Procedures may Challenge Growth

  • The main factors that will hinder market growth in the future are strict government regulations and a reduction in approvals for many small molecules and biologics within developed countries. Small-scale products without state-of-the-art equipment will likely face higher process errors, lack of quality, and increased pricing challenges which could hinder market growth.

Request Free Customization of this report to help us to meet your business objectives.

Liver Cancer Drugs Market Competitive Landscape

The liver cancer therapeutics market is consolidated in nature with the presence of a handful of players. The key market players are focusing on R&D to bring innovative treatments for the treatment of liver cancer. The entry of new players may create a challenging environment for existing players. Increase in efforts such as collaboration, merger and acquisition strategies, among others are likely to help players gain a competitive edge in the overall market competition during the forecast period.

Liver Cancer Drugs Market Top Player’s Company Profile

  • Exelixis, Inc. 
  • Merck KGaA 
  • Bristol-Myers Squibb Company 
  • Bayer AG 
  • Thermo Fisher Scientific Inc. 
  • Pfizer Inc. 
  • Eli Lilly and Company 
  • F. Hoffmann-La Roche Ltd 
  • Novartis AG 
  • Abbott Laboratories 
  • Gilead Sciences 
  • Zydus Pharmaceuticals Inc 
  • AbbVie Inc. 
  • Johnson & Johnson Services Inc. 

Liver Cancer Drugs Market Recent Developments

  • January 2021- F. Hoffmann-La Roche Ltd. revealed their update of survival data from the Phase III IMbrave150 clinical study. This trial examined the effectiveness of a combination therapy that involves the use of Avastin and Tecentriq for treating patients with liver cancer.
  • November 2020- F. Hoffmann-La Roche Ltd. announced the approval of Tecentriq in conjunction with Avastin for treating liver cancer by the European Commision (EU). Their key objective was to expand their product line and promote their brand in the European market.
  • May 2020- The U.S Food and Drug Administration declared the use of Atezolizumab and bevacizumab in combination for the initial treatment of liver cancer.

Liver Cancer Drugs Key Market Trends

  • Robust R&D by Companies to Improve Market Potential: The primary objective of cancer treatment encompasses prolong patient survival, achieving disease cure through therapeutic drugs, and improving overall quality of life. Extensive focus has been directed towards researching and developing immunotherapy and targeted medication therapy, given the crucial role immune cells play in the progression of tumors. As an example, in January 2020, Sirnaomics and Innovent Biologics Inc. joined forces in a collaborative agreement for conducting a clinical research on the medication of Tyvy and the RNAi drug candidate STP705, aiming to treat liver cancer including HCC. Consequently , the realm of liver cancer research and development has witnessed remarkable progress, propelled by strategic partnerships among industry players, leading to a subsequent expansion in the market size for this disease.

Liver Cancer Drugs Market SkyQuest Analysis

SkyQuest’s ABIRAW (Advanced Business Intelligence, Research & Analysis Wing) is our Business Information Component types team that Collects, Collates, Correlates, andAnalyses the Data collected by means of Primary Exploratory Research backed by robust Secondary Desk research.

According to our liver cancer drug market analyses, The impact of COVID-19 on the world has been unprecedented and astounding, with positive demand shocks for liver cancer therapeutics occurring in all regions as a result of the pandemic. The market's growth and demand, which abruptly increased CAGR, will subside after the pandemic is over and the market returns to pre-epidemic levels. The large number of healthcare facilities and the developed infrastructure, after that North America used to dominate the business. Despite this, the Asia Pacific region is predicted to increase at the quickest rate due to the expansion of healthcare in developing countries. As per categorization by end-user, the hospitals and diagnostic laboratories segment dominated the market.

Report Metric Details
Market size value in 2023 USD 3.18 Billion
Market size value in 2032 USD 13.64 Billion
Growth Rate 17.6%
Base year 2024
Forecast period 2025-2032
Forecast Unit (Value) USD Billion
Segments covered
  • Drug
    • Targeted Therapy, Immunotherapy, Chemotherapy
  • Type
    • Hepatocellular Carcinoma, Cholangio Carcinoma, Hepatoblastoma, Others
  • Distribution Chanel
    • Hospital Pharmacy, Retail Pharmacy, Online Pharmacy
Regions covered North America (US, Canada), Europe (Germany, France, United Kingdom, Italy, Spain, Rest of Europe), Asia Pacific (China, India, Japan, Rest of Asia-Pacific), Latin America (Brazil, Rest of Latin America), Middle East & Africa (South Africa, GCC Countries, Rest of MEA)
Companies covered
  • Exelixis, Inc. 
  • Merck KGaA 
  • Bristol-Myers Squibb Company 
  • Bayer AG 
  • Thermo Fisher Scientific Inc. 
  • Pfizer Inc. 
  • Eli Lilly and Company 
  • F. Hoffmann-La Roche Ltd 
  • Novartis AG 
  • Abbott Laboratories 
  • Gilead Sciences 
  • Zydus Pharmaceuticals Inc 
  • AbbVie Inc. 
  • Johnson & Johnson Services Inc. 
Customization scope

Free report customization with purchase. Customization includes:-

  • Segments by type, application, etc
  • Company profile
  • Market dynamics & outlook
  • Region

To get a free trial access to our platform which is a one stop solution for all your data requirements for quicker decision making. This platform allows you to compare markets, competitors who are prominent in the market, and mega trends that are influencing the dynamics in the market. Also, get access to detailed SkyQuest exclusive matrix.

Buy The Complete Report to read the analyzed strategies adopted by the top vendors either to retain or gain market share

Table Of Content

Executive Summary

Market overview

  • Exhibit: Executive Summary – Chart on Market Overview
  • Exhibit: Executive Summary – Data Table on Market Overview
  • Exhibit: Executive Summary – Chart on Liver Cancer Drugs Market Characteristics
  • Exhibit: Executive Summary – Chart on Market by Geography
  • Exhibit: Executive Summary – Chart on Market Segmentation
  • Exhibit: Executive Summary – Chart on Incremental Growth
  • Exhibit: Executive Summary – Data Table on Incremental Growth
  • Exhibit: Executive Summary – Chart on Vendor Market Positioning

Parent Market Analysis

Market overview

Market size

  • Market Dynamics
    • Exhibit: Impact analysis of DROC, 2021
      • Drivers
      • Opportunities
      • Restraints
      • Challenges
  • SWOT Analysis

KEY MARKET INSIGHTS

  • Technology Analysis
    • (Exhibit: Data Table: Name of technology and details)
  • Pricing Analysis
    • (Exhibit: Data Table: Name of technology and pricing details)
  • Supply Chain Analysis
    • (Exhibit: Detailed Supply Chain Presentation)
  • Value Chain Analysis
    • (Exhibit: Detailed Value Chain Presentation)
  • Ecosystem Of the Market
    • Exhibit: Parent Market Ecosystem Market Analysis
    • Exhibit: Market Characteristics of Parent Market
  • IP Analysis
    • (Exhibit: Data Table: Name of product/technology, patents filed, inventor/company name, acquiring firm)
  • Trade Analysis
    • (Exhibit: Data Table: Import and Export data details)
  • Startup Analysis
    • (Exhibit: Data Table: Emerging startups details)
  • Raw Material Analysis
    • (Exhibit: Data Table: Mapping of key raw materials)
  • Innovation Matrix
    • (Exhibit: Positioning Matrix: Mapping of new and existing technologies)
  • Pipeline product Analysis
    • (Exhibit: Data Table: Name of companies and pipeline products, regional mapping)
  • Macroeconomic Indicators

COVID IMPACT

  • Introduction
  • Impact On Economy—scenario Assessment
    • Exhibit: Data on GDP - Year-over-year growth 2016-2022 (%)
  • Revised Market Size
    • Exhibit: Data Table on Liver Cancer Drugs Market size and forecast 2021-2027 ($ million)
  • Impact Of COVID On Key Segments
    • Exhibit: Data Table on Segment Market size and forecast 2021-2027 ($ million)
  • COVID Strategies By Company
    • Exhibit: Analysis on key strategies adopted by companies

MARKET DYNAMICS & OUTLOOK

  • Market Dynamics
    • Exhibit: Impact analysis of DROC, 2021
      • Drivers
      • Opportunities
      • Restraints
      • Challenges
  • Regulatory Landscape
    • Exhibit: Data Table on regulation from different region
  • SWOT Analysis
  • Porters Analysis
    • Competitive rivalry
      • Exhibit: Competitive rivalry Impact of key factors, 2021
    • Threat of substitute products
      • Exhibit: Threat of Substitute Products Impact of key factors, 2021
    • Bargaining power of buyers
      • Exhibit: buyers bargaining power Impact of key factors, 2021
    • Threat of new entrants
      • Exhibit: Threat of new entrants Impact of key factors, 2021
    • Bargaining power of suppliers
      • Exhibit: Threat of suppliers bargaining power Impact of key factors, 2021
  • Skyquest special insights on future disruptions
    • Political Impact
    • Economic impact
    • Social Impact
    • Technical Impact
    • Environmental Impact
    • Legal Impact

Market Size by Region

  • Chart on Market share by geography 2021-2027 (%)
  • Data Table on Market share by geography 2021-2027(%)
  • North America
    • Chart on Market share by country 2021-2027 (%)
    • Data Table on Market share by country 2021-2027(%)
    • USA
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • Canada
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
  • Europe
    • Chart on Market share by country 2021-2027 (%)
    • Data Table on Market share by country 2021-2027(%)
    • Germany
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • Spain
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • France
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • UK
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • Rest of Europe
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
  • Asia Pacific
    • Chart on Market share by country 2021-2027 (%)
    • Data Table on Market share by country 2021-2027(%)
    • China
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • India
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • Japan
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • South Korea
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • Rest of Asia Pacific
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
  • Latin America
    • Chart on Market share by country 2021-2027 (%)
    • Data Table on Market share by country 2021-2027(%)
    • Brazil
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • Rest of South America
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
  • Middle East & Africa (MEA)
    • Chart on Market share by country 2021-2027 (%)
    • Data Table on Market share by country 2021-2027(%)
    • GCC Countries
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • South Africa
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • Rest of MEA
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)

KEY COMPANY PROFILES

  • Competitive Landscape
    • Total number of companies covered
      • Exhibit: companies covered in the report, 2021
    • Top companies market positioning
      • Exhibit: company positioning matrix, 2021
    • Top companies market Share
      • Exhibit: Pie chart analysis on company market share, 2021(%)

Methodology

For the Liver Cancer Drugs Market, our research methodology involved a mixture of primary and secondary data sources. Key steps involved in the research process are listed below:

1. Information Procurement: This stage involved the procurement of Market data or related information via primary and secondary sources. The various secondary sources used included various company websites, annual reports, trade databases, and paid databases such as Hoover's, Bloomberg Business, Factiva, and Avention. Our team did 45 primary interactions Globally which included several stakeholders such as manufacturers, customers, key opinion leaders, etc. Overall, information procurement was one of the most extensive stages in our research process.

2. Information Analysis: This step involved triangulation of data through bottom-up and top-down approaches to estimate and validate the total size and future estimate of the Liver Cancer Drugs Market.

3. Report Formulation: The final step entailed the placement of data points in appropriate Market spaces in an attempt to deduce viable conclusions.

4. Validation & Publishing: Validation is the most important step in the process. Validation & re-validation via an intricately designed process helped us finalize data points to be used for final calculations. The final Market estimates and forecasts were then aligned and sent to our panel of industry experts for validation of data. Once the validation was done the report was sent to our Quality Assurance team to ensure adherence to style guides, consistency & design.

Analyst Support

Customization Options

With the given market data, our dedicated team of analysts can offer you the following customization options are available for the Liver Cancer Drugs Market:

Product Analysis: Product matrix, which offers a detailed comparison of the product portfolio of companies.

Regional Analysis: Further analysis of the Liver Cancer Drugs Market for additional countries.

Competitive Analysis: Detailed analysis and profiling of additional Market players & comparative analysis of competitive products.

Go to Market Strategy: Find the high-growth channels to invest your marketing efforts and increase your customer base.

Innovation Mapping: Identify racial solutions and innovation, connected to deep ecosystems of innovators, start-ups, academics, and strategic partners.

Category Intelligence: Customized intelligence that is relevant to their supply Markets will enable them to make smarter sourcing decisions and improve their category management.

Public Company Transcript Analysis: To improve the investment performance by generating new alpha and making better-informed decisions.

Social Media Listening: To analyze the conversations and trends happening not just around your brand, but around your industry as a whole, and use those insights to make better Marketing decisions.

$5,300
BUY NOW

REQUEST FOR SAMPLE

Want to customize this report?
REQUEST FREE CUSTOMIZATION

FAQs

Liver Cancer Drugs Market size was valued at USD 3.18 Billion in 2023 and is poised to grow from USD 3.74 Billion in 2024 to USD 13.64 Billion by 2032, growing at a CAGR of 17.6% during the forecast period (2025-2032).

The liver cancer therapeutics market is consolidated in nature with the presence of a handful of players. The key market players are focusing on R&D to bring innovative treatments for the treatment of liver cancer. The entry of new players may create a challenging environment for existing players. Increase in efforts such as collaboration, merger and acquisition strategies, among others are likely to help players gain a competitive edge in the overall market competition during the forecast period. 'Exelixis, Inc. ', 'Merck KGaA ', 'Bristol-Myers Squibb Company ', 'Bayer AG ', 'Thermo Fisher Scientific Inc. ', 'Pfizer Inc. ', 'Eli Lilly and Company ', 'F. Hoffmann-La Roche Ltd ', 'Novartis AG ', 'Abbott Laboratories ', 'Gilead Sciences ', 'Zydus Pharmaceuticals Inc ', 'AbbVie Inc. ', 'Johnson & Johnson Services Inc. '

One million new cases of liver cancer are diagnosed worldwide each year. The increase in prevalence of people consuming alcohol and following smoking habits is projected to aid in market expansion during the forecast period. Liver cancer is mainly caused by smoking, alcohol, and increased urbanization. The global market for liver cancer drugs is being positively impacted by increased government help and investments from international healthcare institutions. The availability of many liver cancer drugs may soon increase demand.

Robust R&D by Companies to Improve Market Potential: The primary objective of cancer treatment encompasses prolong patient survival, achieving disease cure through therapeutic drugs, and improving overall quality of life. Extensive focus has been directed towards researching and developing immunotherapy and targeted medication therapy, given the crucial role immune cells play in the progression of tumors. As an example, in January 2020, Sirnaomics and Innovent Biologics Inc. joined forces in a collaborative agreement for conducting a clinical research on the medication of Tyvy and the RNAi drug candidate STP705, aiming to treat liver cancer including HCC. Consequently , the realm of liver cancer research and development has witnessed remarkable progress, propelled by strategic partnerships among industry players, leading to a subsequent expansion in the market size for this disease.

North America held the dominant share with an estimated 40.37% share earned in 2022. This is owing to the presence of well-established healthcare infrastructure, coupled with an extensive reimbursement framework. Additionally, the increasing implementation of novel diagnostics, and adoption of healthcare insurance policies will further help this region continue dominance. Furthermore, due to the rising incidence of various tumor cases, supportive government organizations such as IARC, CDC, and NIH, the research & development of new testing & screening methods is also projected to help promote market growth.

Request Free Customization

Want to customize this report? This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time. We offer $1000 worth of FREE customization at the time of purchase.

logo-images

Feedback From Our Clients

Liver Cancer Drugs Market

Report ID: SQMIG35B2174

sales@skyquestt.com
USA +1 351-333-4748

BUY NOW GET FREE SAMPLE

This site uses cookies. See Our Privacy And Policy For More info.